Go Pro
→ One Ticker Tied to a Major White House Move You Should Know (From Brownstone Research) (Ad)tc pixel Free SVRA Stock Alerts

Savara (SVRA) News Today

Savara logo
$5.59 +0.10 (+1.82%)
As of 08/21/2026 04:00 PM Eastern
Compare

Savara Latest News

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance
August 20 at 11:17 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SVRA/press-releases/
HC Wainwright Issues Negative Outlook for Savara Earnings
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963133
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-walleye-capital-llc-invests-153-million-in-savara-inc-svra-2026-08-15/
What is HC Wainwright's Estimate for Savara FY2029 Earnings?
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961881
Savara (NASDAQ:SVRA) Lowered to Sell Rating by Wall Street Zen
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961531
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-nasdaqsvra-stock-rating-lowered-by-wall-street-zen-2026-08-15/
HC Wainwright Brokers Lower Earnings Estimates for Savara
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-brokers-lower-earnings-estimates-for-savara-2026-08-14/
Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-nasdaqsvra-stock-price-down-54-whats-next-2026-08-13/
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-pessimistic-view-of-savara-fy2029-earnings-2026-08-13/
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-nasdaqsvra-releases-quarterly-earnings-results-misses-expectations-by-002-eps-2026-08-11/
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-savara-inc-svra-shares-bought-by-renaissance-technologies-llc-2026-08-08/
Savara (SVRA) to Announce Quarterly Earnings on Wednesday
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-svra-to-announce-quarterly-earnings-on-wednesday-2026-08-05/
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930599-savara-high-potential-binary-bet-cruising-to-pdufa-after-3-month-speed-bump
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-grows-stock-holdings-in-savara-inc-svra-2026-08-02/
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-inc-nasdaqsvra-receives-consensus-rating-of-moderate-buy-from-brokerages-2026-07-30/
Savara Inc. $SVRA Shares Bought by Eversept Partners LP
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-savara-inc-svra-shares-bought-by-eversept-partners-lp-2026-07-28/
Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-orbimed-advisors-llc-acquires-shares-of-635000-savara-inc-svra-2026-07-27/
Savara Inc. $SVRA Stock Position Boosted by Spruce Street Capital LP
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-savara-inc-svra-stock-position-boosted-by-spruce-street-capital-lp-2026-07-25/
Affinity Asset Advisors LLC Decreases Stock Holdings in Savara Inc. $SVRA
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-affinity-asset-advisors-llc-decreases-stock-holdings-in-savara-inc-svra-2026-07-25/
Savara (SVRA) Gets a Buy from Piper Sandler
July 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/3422910/savara-svra-gets-a-buy-from-piper-sandler/
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
June 27, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/27/what-savara-investors-should-know-about-this-580-187-option-exercise-and-fda-timeline/
Savara Announces New Employment Inducement Grant
June 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260612214793/en/savara-announces-new-employment-inducement-grant/
Savara Announces Chief Financial and Administrative Officer Transition
June 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260608876987/en/savara-announces-chief-financial-and-administrative-officer-transition/
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
June 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/assessing-savara-svra-valuation-shares-171334905.html
Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)
June 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/2303559/oppenheimer-sticks-to-their-buy-rating-for-savara-svra/
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)
May 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/2214987/analysts-offer-insights-on-healthcare-companies-savara-svra-and-biogen-biib/
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260527034505/en/savara-announces-participation-in-the-2026-jefferies-global-healthcare-conference/
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
May 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4909114-savara-stock-rare-disease-funnel-is-becoming-a-commercial-asset
Savara Inc. (SVRA) Reports Q1 Financial Results
May 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/savara-inc-svra-reports-q1-financial-results-1767480/
5 Best Penny Stocks to Buy for Long Term
May 21, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-best-penny-stocks-to-buy-for-long-term-1765440/
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
May 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260520792505/en/savara-presented-new-biomarker-data-from-the-impala-2-phase-3-clinical-trial-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-at-the-american-thoracic-society-ats-international-conference-2026/
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar ...
May 19, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-exercise-capacity-data-185500185.html
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519029544/en/savara-presented-long-term-efficacy-and-safety-data-from-the-ongoing-impala-2-phase-3-clinical-trial-open-label-ol-extension-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap/
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
May 18, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260518925976/en/savara-announces-new-exercise-capacity-data-from-the-impala-2-phase-3-clinical-trial-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap/
Guggenheim Reaffirms Their Buy Rating on Savara (SVRA)
May 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/1928793/guggenheim-reaffirms-their-buy-rating-on-savara-svra/
Savara (SVRA) Receives a Buy from Piper Sandler
May 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/1929432/savara-svra-receives-a-buy-from-piper-sandler/
Savara Reports First Quarter Financial Results and Provides Business Update
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512677993/en/savara-reports-first-quarter-financial-results-and-provides-business-update/
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim
April 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/assessing-savara-svra-valuation-fda-170321523.html
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Rhythm Pharmaceuticals (RYTM)
April 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM-Q/pressreleases/1365090/analysts-offer-insights-on-healthcare-companies-savara-svra-and-rhythm-pharmaceuticals-rytm/
Savara Announces New Employment Inducement Grant
April 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260417883325/en/savara-announces-new-employment-inducement-grant/
Savara gets FDA review extension for lead asset
April 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4575623-savara-gets-fda-review-extension-for-lead-asset
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application ...
April 15, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-u-food-drug-200500011.html
SVRA stock slips post-market after FDA delays decision on pulmonary therapy
April 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/svra-stock-slips-post-market-after-fda-delays-decision-on-pulmonary-therapy/ar-AA20Z9X5
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
April 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260415775650/en/savara-announces-the-u.s.-food-drug-administration-fda-has-extended-the-review-period-for-the-molgramostim-inhalation-solution-molgramostim-biologics-license-application-bla-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap/
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
April 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260414233320/en/savara-to-present-new-data-at-the-american-thoracic-society-ats-2026-international-conference/
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune ...
April 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/savara-announces-u-k-medicines-120500132.html
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
April 7, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260407024140/en/savara-announces-the-u.k.-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi*-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap/
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Edwards Lifesciences (EW)
April 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA/pressreleases/1071898/analysts-offer-insights-on-healthcare-companies-savara-svra-and-edwards-lifesciences-ew/
Guggenheim Keeps Their Buy Rating on Savara (SVRA)
April 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA/pressreleases/1086379/guggenheim-keeps-their-buy-rating-on-savara-svra/
Savara Inc.
April 1, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/SVRA/company-profile

Savara Media Mentions By Week

Savara Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SVRA
News Sentiment
▼
0.09

0.62
▲
Average
Healthcare
News Sentiment

Savara News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SVRA Articles
This Week
▼
2

8
▲
SVRA Articles
Average Week

Savara Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
4
+100%
Page Views
3,044
-4%
Get Savara News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

This page (NASDAQ:SVRA) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Elon Musk, Peter Thiel, Sam Altman Are Teaming Up to Back THIS New AI
Elon Musk, Peter Thiel, and Sam Altman are backing a new AI use case discovered at MIT that has already identi...
Stansberry Research | Sponsoredtc pixel